about
Development of a method to detect and quantify Aspergillus fumigatus conidia by quantitative PCR for environmental air samplesEcology of aspergillosis: insights into the pathogenic potency of Aspergillus fumigatus and some other Aspergillus speciesAzole Resistance in Aspergillus fumigatus: Can We Retain the Clinical Use of Mold-Active Antifungal Azoles?Invasive aspergillosis in the intensive care unitIn vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp.Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosisCharacterization of the FKBP12-Encoding Genes in Aspergillus fumigatusAspergillus fumigatus and aspergillosisChronic granulomatous disease presenting with disseminated intracranial aspergillosis.Peroral amphotericin B polymer nanoparticles lead to comparable or superior in vivo antifungal activity to that of intravenous Ambisome® or Fungizone™.CNS aspergillosis: recognition, diagnosis and management.A 4'-phosphopantetheinyl transferase mediates non-ribosomal peptide synthetase activation in Aspergillus fumigatus.Aspergillosis case-fatality rate: systematic review of the literature.A nonribosomal peptide synthetase (Pes1) confers protection against oxidative stress in Aspergillus fumigatus.The safety of interferon-gamma-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation.Lung resection for invasive pulmonary aspergillosis in neutropenic patients with hematologic diseases.Disseminated aspergillosis caused by Aspergillus ustus in a patient following allogeneic peripheral stem cell transplantation.Outbreak of invasive pulmonary aspergillosis among patients hospitalized in a bone marrow transplant ward: tomographic findings.Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion.Antifungal activity of the pradimicin derivative BMS 181184 in the treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits.Combination therapy for chronic invasive rhinocerebral aspergillosis in a clinically immunocompetent patient.The developmentally regulated alb1 gene of Aspergillus fumigatus: its role in modulation of conidial morphology and virulence.Purine Acquisition and Synthesis by Human Fungal Pathogens.Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America.Voriconazole: a new triazole antifungal.Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive Aspergillosis.Quantitative galactomannan detection is superior to PCR in diagnosing and monitoring invasive pulmonary aspergillosis in an experimental rat modelIdentification of Aspergillus species using internal transcribed spacer regions 1 and 2.Pulmonary infection caused by Gymnascella hyalinospora in a patient with acute myelogenous leukemia.Aspergillus Fumigatus antigen detection in sera from patients at risk for invasive aspergillosis.A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan.Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus.Comparison of commercial latex agglutination and sandwich enzyme immunoassays with a competitive binding inhibition enzyme immunoassay for detection of antigenemia and antigenuria in a rabbit model of invasive aspergillosis.Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997.Review of comparative studies between conventional and liposomal amphotericin B (Ambisome) in neutropenic patients with fever of unknown origin and patients with systemic mycosis.Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infectionsUptake of Aspergillus fumigatus Conidia by phagocytic and nonphagocytic cells in vitro: quantitation using strains expressing green fluorescent protein.Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis.Surgical treatment of mediastinal aspergilloma in a immunocompetent patient.
P2860
Q23914280-2F22D0C9-A810-4C0F-AAA1-4EF1772D63C4Q26748172-70604BA6-EB97-42E5-B9FB-9D861119C0EBQ28082352-080EEEB9-9ACE-41FB-A2B0-F28E55FC6363Q28306909-B705F7D2-1F77-486F-ABF5-969F9B932AA7Q28369044-6887077D-B5F7-4A7D-9ECB-7DD11A90530EQ28379470-D316014D-B885-4AA8-A72B-10132DBF2705Q28547946-AEA922FA-9371-49A1-BDFC-9F9177CF6509Q29617908-95C12073-8959-495C-A63D-79B8BB71CC69Q30991211-621C95AD-6243-422C-995A-177A508862D5Q31037255-C08D4A20-CE17-4B01-9795-1A2EBDFEE5EAQ31118905-BEBA8B08-9D4A-42EA-B922-894A556E0B8AQ31148356-5DCA39C0-8562-4AF9-A235-CB310C060F9DQ31918085-1922BD70-1CBD-4B20-B468-F714CCE4348AQ33246026-A32EEE9A-04F1-43B1-8D8D-E497BAAB0A52Q33364468-FE22F48C-C224-46FF-9990-5843B72F1199Q33503546-F791C749-74FB-47AC-B741-BAE43EC3BFFAQ33504338-65698E5D-A3E7-4FAD-AD26-DF908EAD5837Q33509825-823B8372-723A-4B21-9D1C-331E6E89C0A8Q33691165-5B5E4A40-C0EC-443D-8824-B17A5EB11411Q33697110-E75AC683-FC46-4E38-AAE8-7C1621929C84Q33738957-4E9E2A85-467C-4B7D-8CAE-75EB38003B06Q33745136-89F9505C-4290-44BA-93B5-1C9D2A00406CQ33845440-F3C13EAF-73C6-4C36-BFFF-9936466D9F3FQ33894472-517E0FDB-C911-4C5D-9E96-D28222E99559Q33917339-6AB7534B-0784-4208-8FC3-4C597BE4274AQ33962952-3CF70FDB-AF99-451D-AFD5-411FC912AC26Q33966364-1E89512B-BFEB-492A-983D-F341851A0E6BQ33966455-3E7818AB-CABD-4C51-BD4E-F7D02C74FC00Q33974908-22859E7B-06AA-4929-B0BF-09A5074109BDQ33974986-567BCC40-960A-409E-8C9E-816A932E805BQ33980368-0AF71B35-C4D5-4D4D-B348-15C43DD5D945Q33983499-7CFC3BAE-50EA-4D5E-955C-79CA66CFDBC2Q33998403-1EB8AFE2-EA64-4A5C-ADE7-7570A116C871Q34085884-7A249476-8604-4BED-B114-D1683CA6B087Q34098069-A05443ED-1AEC-4B5E-AA0A-C4CA36F902E5Q34104748-C831C293-C981-439E-A288-CB092D1E2851Q34108585-F97E3B8E-ACB3-494D-8CDF-FBDF77039A7BQ34122696-8C27A373-F78A-4C3E-9E37-A56A7C4AC5EFQ34143326-C85D5F70-6880-4774-90F0-0AFED13FB58BQ34148463-19C171BB-EFD1-40F6-89B2-5F0672C96AB9
P2860
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
Therapeutic outcome in invasive aspergillosis.
@en
type
label
Therapeutic outcome in invasive aspergillosis.
@en
prefLabel
Therapeutic outcome in invasive aspergillosis.
@en
P356
P1476
Therapeutic outcome in invasive aspergillosis.
@en
P2093
Denning DW
P304
P356
10.1093/CLINIDS/23.3.608
P407
P577
1996-09-01T00:00:00Z